Acumen, JCR partner to enhance Alzheimer’s therapy delivery
The partnership combines Acumen's expertise in amyloid beta oligomer-selective antibodies with JCR's blood-brain barrier-penetrating technology, to improve AD treatment delivery.

A leading resource for the Pharmaceutical industry since 2002
The partnership combines Acumen's expertise in amyloid beta oligomer-selective antibodies with JCR's blood-brain barrier-penetrating technology, to improve AD treatment delivery.
Chemspec Europe 2025 returns to Cologne with expanded exhibition space, enhanced digital tools, and a diverse line-up of industry leaders. This premier event will showcase cutting-edge solutions across key sectors,...
Seal the deal
Excipient evolution shaping pharma innovation
Solving the EDDO guidance puzzle
AI-driven delivery